Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Adicet Bio, Inc. (ACET)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.04+0.07 (+0.88%)
At close: 4:00PM EDT
8.04 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.97
Open8.14
Bid7.36 x 800
Ask8.30 x 1200
Day's Range7.86 - 8.31
52 Week Range6.25 - 17.80
Volume84,359
Avg. Volume93,701
Market Cap255.781M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.02
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.29
  • GlobeNewswire

    Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer

    MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer. In this role, Dr. Aftab will be responsible for the continued expansion of Adicet’s pipeline of therapeutic candidates in solid and hematolo

  • GlobeNewswire

    Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting

    MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held November 10-14, 2021. Details of the poster presentation: Title: ADI-002: an IL-15 armored a

  • GlobeNewswire

    Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

    MENLO PARK, Calif., and BOSTON, MA, and SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, and Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration to accelerate the discover

Advertisement
Advertisement